Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mevo Health vs Remi Meds

Mevo Health
Graded #327

Higher grade

vs+11.800000000000004
Remi Meds
Graded #493

Lower grade

The verdict

Mevo Health takes it — 60.2/100 to 48.4/100.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +22
56
34
Dose & formulationMevo Health +29
83
54
Clinical oversightMevo Health +13
67
54
Labs & monitoringMevo Health +2
52
50
FulfillmentMevo Health +4
57
53
Contract termsRemi Meds +35
20
55
Mevo Health · left barRemi Meds · right bar

The numbers

MetricMevo HealthRemi Meds
WeighScore60.2/10048.4/100
GradeCC
Scorecard rank#327#493
Semaglutide$199/mo (all doses, compounded)$249/mo (0.25 mg dose, compounded)
Tirzepatide$259/mo (all doses, compounded)$349/mo (2.25 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Mevo Health

Graded #327 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed
Remi Meds

Graded #493 · C

Strengths

  • Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
  • LegitScript verification badge on the homepage
  • Publishes 503A FDCA compliance language on the tirzepatide page
  • Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
  • Operating corporate entity disclosed (T-C Health Co)

Where it loses points

  • No named medical director, founder, or physician on any public page
  • States served not listed — 'nationwide' claim with no per-state detail
  • Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
  • Year founded and corporate history are opaque
  • Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard